Modern principles of maintaining sinus rhythm in atrial fibrillation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There are two main directions in the drug treatment of patients with atrial fibrillation (AF): cardiac rhythm managment and ventricular contraction rate (VCR) control. The advantages of the VCR control tactics in AF include good tolerance of drugs and the absence of side effects; the disadvantage is the persistence of arrhythmia symptoms. Restoring and maintaining sinus rhythm in AF patients can reduce arrhythmia symptoms. However, the effectiveness of treatment with the use of most antiarrhythmic drugs remains very low, and the risk of side effects is quite high. Recently, the results of a new clinical trial, EAST-AFNET 4, have been published. It has been convincingly demonstrated that sinus rhythm maintenance is the preferred strategy for treating AF patients, which includes radiofrequency ablation with concurrent administration of anticoagulants and antiarrhythmic drugs.

Full Text

Restricted Access

About the authors

A. I Tarzimanova

Sechenov First Moscow State Medical University

Email: tarzimanova@mail.rn
Dr. Sci. (Med.), Professor at the Department of Faculty Therapy №2 8, build. 2, Trubetskaya str., Moscow 119991, Russian Federation

References

  1. Benjamin E.J., Muntner P, Alonso A., et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e528. Doi: 10.1161/ CIR.0000000000000659.
  2. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Aug 29;ehaa612. doi: 10.1093/eurheartj/ ehaa612.
  3. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. doi: 10.1056/NEJMoa021328.
  4. Carlsson J. STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol. 2003;41:1690-96. doi: 10.1016/s0735-1097(03)00332-2.
  5. Hohnloser S.H. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-94. doi: 10.1016/s0140-6736(00)03230-x.
  6. Opolski G. Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126(2):476-86.
  7. Roy D. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. Doi: 10.1056/ NEJMoa0708789.
  8. Van Gelder I.C. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. Doi: 10.1056/ NEJMoa1001337.
  9. Van Gelder I.C. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. doi: 10.1056/NEJMoa021375.
  10. Ionescu-Ittu R., et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 2012;172:997 doi: 10.1001/archinternmed.2012.2266.
  11. Caldeira D. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012;105:226-38. Doi: 10.1016/j. acvd.2011.11.005.
  12. Chen S. Should rhythm control be preferred in younger atrial fibrillation patients? J Interv Card Electrophysiol. 2012;22:34-9.
  13. De Vos C.B. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012;163:88 7-93. doi: 10.1016/j.ahj.2012.02.015.
  14. Kirchhof P, Camm A.J., Goette A., et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-16. doi: 10.1056/NEJMoa2019422.
  15. January C.T., Wann L.S., Calkins H., et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, Heart Rhythm 2019. doi: 10.1016/j.hrthm.2019.01.024.
  16. Тарасов А.В., Давтян К.В., Шатахцян В.С. Эффективность антиаритмической терапии для разных типов рецидивов предсердных тахиаритмий в раннем послеоперационном периоде катетрной изоляции устьев легочных вен. Кардиология и сердечно-сосудистая хирургия. 2017;2:70-7. Doi: 10.17116/ kardio201710270-77.
  17. Подзолков В.И., Тарзиманова А.И. Антиаритмическая терапия в лечении фибрилляции предсердий: вчера, сегодня, завтра. Кардиоваскулярная терапия и профилактика. 2019;18(3):81 -7. doi: 10.15829/1728-8800-2019-3-81-87
  18. Stoschitzky K, Stoschitzky G, Lercher P, et al. Propafenone shows class Ic and class II antiarrhythmic effects. Europace. 2016; 18(4):568-71. doi: 10.1093/europace/etv195.
  19. Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;16(5):CD005049. doi: 10.1002/14651858.CD005049.pub3.
  20. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19(4):2630. doi: 10.15829/1728-8800-2020-2630.
  21. Миллер О.Н., Старичков С.А., Поздняков Ю.М. и др. Эффективность и безопасность применения пропафенона (пропанорма) и амиодарона (кордарона) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010;4(84):56-72
  22. Kirchhof P, Lip G.Y., Van Geider I.C., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork. Europace. 2012;14:8-27. doi: 10.1093/europace/ eur241.
  23. Parvez B., Vagiio J., Rowan S., et ai. Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Poiymorphismin Atriai Fibrillation. J Am Coii Cardiol. 2012;60(6):539-45. doi: 10.1016/j.jacc.2012.01.070.
  24. Подзолков В.И., Тарзиманова А.И. Персонализированная медицина в лечении фибрилляции предсердий: миф или реальность? Рациональная фармакотерапия в кардиологии. 2019;15(1 ):90-4. doi: 10.20996/1819-6446-2019-15-1-90-94.
  25. Arbeio E., Brugada J., Hindricks G. Study Investigators. ESC-EURObservationai Research Programme: the Atriai Fibriiiation Abiation Piiot Study, conducted by the European Heart Rhythm Association. Europace. 2012;14:10.
  26. Arbeio E., Brugada J., Hindricks G., et ai. Atriai Fibriiiation Abiation Piiot Study Investigators. The atriai fibriiiation abiation piiot study: a European Survey on Methodoiogy and resuits of catheter abiation for atriai fibriiiation conducted by the European Heart Rhythm Association. Eur Heart J. 2014;35:1466-78. doi: 10.1093/eurheartj/ ehu001.
  27. Arbeio E., Brugada J., Biomstrom-Lundqvist C., et ai. Long-term Registry Investigators. Contemporary management of patients undergoing atriai fibriiiation abiation: in-hospitai and 1-year foiiow-up findings from the ESC-EHRA atria. Eur Heart J. 2017;38:1303-16. doi: 10.1093/eurheartj/ehw564.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies